EU funded systems biology consortium for adipositas induced type-2 diabetes reports first results
The strategy to achieve SysProts objective is an innovative, explorative systems biology approach, both on the molecular and physiological level with a strong focus on protein function and modification. The project is producing high quality proteomics data indispensable for the identification of novel circulating protein factors and posttranslational protein modifications that are important for the onset, dynamics and progression of adipositas and type II diabetes. Data generation is complemented by the development of computational analysis methods for these novel data types and creation of an adequate modelling technology. Recently the pharmaceutical company Pfizer has launched a comparable US$ 14-million systems-biology consortium to improve the understanding of diabetes and obesity.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.